| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1432-2277.2005.00163.X |
| P8608 | Fatcat ID | release_f7ue562gjbgvxfxxvisntsx5xu |
| P698 | PubMed publication ID | 16101723 |
| P5875 | ResearchGate publication ID | 7658335 |
| P2093 | author name string | Josep M Campistol | |
| Martine Gioud-Paquet | |||
| David W Holt | |||
| Solomon Epstein | |||
| James T Burke | |||
| Karine Rutault | |||
| Sirolimus European Renal Transplant Study Group* | |||
| P2860 | cites work | Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group | Q28374428 |
| Rapamycin in transplantation: a review of the evidence | Q31789323 | ||
| Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells | Q31855305 | ||
| Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients | Q33332340 | ||
| Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure | Q33339056 | ||
| Mechanism of transplantation-associated bone loss | Q33982249 | ||
| Biochemical markers of bone metabolism: an overview | Q41696180 | ||
| Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation | Q43453547 | ||
| Osteoporosis after renal transplantation: single center experience | Q43567961 | ||
| Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. | Q51597446 | ||
| Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study | Q57943257 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cyclosporine | Q367700 |
| P304 | page(s) | 1028-1035 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Transplant International | Q15762140 |
| P1476 | title | Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus | |
| P478 | volume | 18 |
| Q39247900 | CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health. |
| Q36327938 | Current Status of Research on Osteoporosis after Solid Organ Transplantation: Pathogenesis and Management |
| Q47390814 | Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. |
| Q84403251 | Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism |
| Q35212798 | Elevated incidence of fractures in solid-organ transplant recipients on glucocorticoid-sparing immunosuppressive regimens |
| Q37822152 | Individualizing early use of sirolimus in renal transplantation |
| Q42795558 | Loss of bone mineral density in renal transplantation recipients |
| Q46915002 | Renal calcium handling after rapamycin conversion in chronic allograft dysfunction |
| Q37720393 | Sirolimus and tacrolimus rather than cyclosporine A cause bone loss in healthy adult male rats. |
| Q28485278 | Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study |
| Q38803449 | Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology |
| Q38161821 | What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy? |
| Q57146434 | mTORC1 impedes osteoclast differentiation via calcineurin and NFATc1 |
Search more.